{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:59:21Z","timestamp":1784552361330,"version":"3.55.0"},"reference-count":109,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To discuss the risk factors, microbial resistance rates, and pharmacotherapy, including antimicrobial choices and medication dosage regimens, for urinary tract infections (UTIs) in pediatric patients.\n                    <jats:bold>Data Sources:<\/jats:bold>\n                    A MEDLINE literature search (1985 to December 2017) was performed using the following keywords and associated medical subject headings:\n                    <jats:italic toggle=\"yes\">urinary tract infection, antimicrobial, treatment<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">children<\/jats:italic>\n                    .\n                    <jats:bold>Study Selection and Data Extraction:<\/jats:bold>\n                    Search was conducted to identify clinical trials, systematic reviews, and guidelines. Search was filtered to include studies with age range between birth and 18 years and published in English. Additional references were identified from selected review articles.\n                    <jats:bold>Data Synthesis:<\/jats:bold>\n                    In total, 27 studies investigating microbial resistance, 31 studies assessing antimicrobial efficacy, 34 studies describing prophylaxis, and 6 systematic reviews were included. The resistance patterns differed across age groups and affected the choice of empirical therapy. If pyelonephritis is suspected, empiric antimicrobials should have high urinary and sufficient parenchymal concentrations. Nitrofurantoin has low microbial resistance rates and can generally be used empirically for treating uncomplicated cystitis in children &gt;1 month of age. Trimethoprim-sulfamethoxazole resistance has increased and should be avoided unless local susceptibility data are available. Certain patients with recurrent UTIs or renal abnormalities may require antimicrobial prophylaxis, which may be associated with adverse effects, such as intolerability or an increased risk of microbial resistance.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The resistance pattern of uropathogens should be considered prior to initiating therapy. Controlled trials with large samples are needed to compare the treatment duration of various antimicrobial regimens and the specific role of prophylactic antimicrobials.\n                  <\/jats:p>","DOI":"10.1177\/8755122518755402","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T02:09:27Z","timestamp":1517450967000},"page":"62-81","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial Pharmacotherapy Management of Urinary Tract Infections in Pediatric Patients"],"prefix":"10.1177","volume":"34","author":[{"given":"Manar O.","family":"Lashkar","sequence":"first","affiliation":[{"name":"King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milap C.","family":"Nahata","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3465."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003772.pub4."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13636."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-1330."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-3026."},{"key":"e_1_3_2_7_2","unstructured":"National Institute for Health and Care Excellence. Urinary tract infection in children. Evidence update October 2013: evidence update 48. https:\/\/arms.evidence.nhs.uk\/resources\/hub\/1029882\/attachment. Published October 2013. Accessed April 15 2015."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.007."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.86.3.363"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.2.179."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.12842."},{"key":"e_1_3_2_12_2","first-page":"264","article-title":"Screening for urinary tract infection in children with cancer","volume":"75","author":"Munyi ST","year":"1998","unstructured":"Munyi ST, Macharia WM, Alwar AJ, Njeru EK. Screening for urinary tract infection in children with cancer. East Afr Med J. 1998;75:264-267.","journal-title":"East Afr Med J"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.100.2.228."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1527."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2013.05.006."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/605530."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902295."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3770."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2926."},{"key":"e_1_3_2_20_2","first-page":"348","article-title":"Neonatal urinary tract infection: clinical response to empirical therapy versus in vitro susceptibility at Bahrami Children\u2019s Hospital-neonatal ward: 2001-2010","volume":"50","author":"Taheri PA","year":"2012","unstructured":"Taheri PA, Navabi B, Shariat M. Neonatal urinary tract infection: clinical response to empirical therapy versus in vitro susceptibility at Bahrami Children\u2019s Hospital-neonatal ward: 2001-2010. Acta Med Iran. 2012;50:348-352.","journal-title":"Acta Med Iran"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2010.09.003."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.07.009."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2583."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.06.053."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.009."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0493-0."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000168743.57286.13."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-7328-4."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1951-5."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.06.078."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2012.03709.x."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0009922814555974."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.002."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9445-5."},{"key":"e_1_3_2_35_2","first-page":"971","article-title":"Community-acquired urinary tract infections in children: pathogens, antibiotic susceptibility and seasonal changes","volume":"17","author":"Yolbas I","year":"2013","unstructured":"Yolbas I, Tekin R, Kelekci S, et al. Community-acquired urinary tract infections in children: pathogens, antibiotic susceptibility and seasonal changes. Eur Rev Med Pharmacol Sci. 2013;17:971-976.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_2_36_2","first-page":"135","article-title":"Empirical treatment for pediatric urinary tract infection and resistance patterns of uropathogens, in Queen Alia hospital and prince A\u2019Isha military center\u2014Jordan","volume":"20","author":"Al-Mardeni RI","year":"2009","unstructured":"Al-Mardeni RI, Batarseh A, Omaish L, Shraideh M, Batarseh B, Unis N. Empirical treatment for pediatric urinary tract infection and resistance patterns of uropathogens, in Queen Alia hospital and prince A\u2019Isha military center\u2014Jordan. Saudi J Kidney Dis Transpl. 2009;20:135-139.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.069."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.10.064."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2013.12.002."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0556-5."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.1960."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31820d7ec4."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13112."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.993381."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.006."},{"key":"e_1_3_2_47_2","unstructured":"National Institute for Health and Care Excellence. Urinary tract infection in 16s: diagnosis and management [Clinical guidelines CG54]. https:\/\/www.nice.org.uk\/guidance\/cg54. Published August 2007. Accessed April 15 2015."},{"key":"e_1_3_2_48_2","unstructured":"Bactrim [package insert]. Philadelphia PA: Mutual Pharmaceutical Company; June 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017377s068s073lbl.pdf. Accessed June 9 2017."},{"key":"e_1_3_2_49_2","unstructured":"Macrobid [package insert]. Cincinnati OH: Procter & Gamble Pharmaceuticals; February 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020064s019lbl.pdf. Accessed June 9 2017."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R352."},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.150067."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14072."},{"key":"e_1_3_2_53_2","unstructured":"US Food and Drug Administration Division of Special Pathogen and Immunologic Drug Products. Clinical review for new drug applications. https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM447421.pdf. Accessed December 1 2017."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-1722."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15."},{"key":"e_1_3_2_56_2","unstructured":"Monurol [package insert]. Cadempino Switzerland: Zambon Switzerland Ltd; July 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050717s005lbl.pdf. Accessed June 20 2017."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1153-z."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001636."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu069."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152."},{"key":"e_1_3_2_61_2","unstructured":"Zerbaxa [package insert]. Lexington MA: Cubist Pharmaceuticals US; December 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf. Accessed June 19 2017."},{"key":"e_1_3_2_62_2","unstructured":"Avycaz [package insert]. Verona Italy: GlaxoSmithKline Manufacturing SpA; February 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494lbl.pdf. Accessed June 9 2017."},{"key":"e_1_3_2_63_2","unstructured":"US National Library of Medicine. Pharmacokinetic and safety study of ceftolozane\/tazobactam in pediatric participants receiving antibiotic therapy for proven or suspected gram-negative infection or for peri-operative prophylaxis (MK-7625A-010). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02266706. Published October 17 2014. Accessed June 19 2017."},{"key":"e_1_3_2_64_2","unstructured":"US National Library of Medicine. Evaluation of safety pharmacokinetics and efficacy of ceftazidime and avibactam (CAZ-AVI) compared with cefepime in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTIs). https:\/\/clinicaltrials.gov\/show\/NCT02497781. Published July 15 2015. Accessed June 19 2017."},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.1.79."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-0814."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.84.3.241."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02549709"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1992.tb12336.x"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003966."},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006857.pub2."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.5.e70."},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.114698."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2948."},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670100690."},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1021."},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.155.2.135"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200103000-00004."},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1080\/08035250310009194."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2007.02370.x."},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2308-4."},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0297."},{"key":"e_1_3_2_83_2","unstructured":"Shaikh N. Corticosteroids for children with febrile urinary tract infections (STARRS). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01391793?term=starrs&rank=1. Published July 12 2011. Accessed April 27 2017."},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.93.5.752"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70364-6"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1362."},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2652."},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2943-z."},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.09.090."},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2011.05.006."},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401811."},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001534.pub3."},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.08.112."},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.3923\/ijp.2007.179.182"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1990.tb11414.x"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.4.509"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02552109"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.1.77."},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0507-1."},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.06.018."},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015606729."},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn489."},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2005.08.009."},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2009.02867.x."},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.02.031."},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir801."},{"key":"e_1_3_2_107_2","first-page":"98","article-title":"Efficacy of cranberry in prevention of urinary tract infection in a susceptible pediatric population","volume":"2","author":"Foda MM","year":"1995","unstructured":"Foda MM, Middlebrook PF, Gatfield CT, Potvin G, Wells G, Schillinger JF. Efficacy of cranberry in prevention of urinary tract infection in a susceptible pediatric population. Can J Urol. 1995;2:98-102.","journal-title":"Can J Urol"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70087-9"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/317280."},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.2147\/OAJCT.S31734"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/8755122518755402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/8755122518755402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/8755122518755402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:28:07Z","timestamp":1777602487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/8755122518755402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1177\/8755122518755402"],"URL":"https:\/\/doi.org\/10.1177\/8755122518755402","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]}}}